Key Players
Competitive Landscape
Four supplier models compete in the fragment-based drug discovery market: integrated CROs, specialist FBDD providers, proprietary drug developers and computational design companies.
Investment has moved toward faster compound synthesis and combined experimental-computational commercial hit-finding programs since 2025. In July 2025, Sygnature Discovery completed a EUR 1 million upgrade that doubled synthesis and purification capacity. In August 2025, Domainex joined Pharmacelera for AI-guided screening and membrane-protein hit finding against difficult targets. Project teams now compare protein readiness, orthogonal confirmation and chemistry continuity first across outsourced programs.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Sygnature Discovery completed a EUR 1 million chemistry upgrade that doubled synthesis and purification capacity in July 2025. | Fragment programs need faster compound supply once validated hits enter analogue design and repeated structure-guided testing. | Integrated CROs place automated synthesis and purification directly beside hit identification and medicinal chemistry teams. | Revenue expands through paid design-make-test cycles that convert confirmed fragments into stronger lead series for sponsors. |
| Domainex joined Pharmacelera for membrane-protein screening and AI-guided virtual design against difficult targets in August 2025. | Difficult membrane targets require stable proteins and wider virtual searches that identify tractable compounds for experimental confirmation. | Specialist CROs increasingly pair physical target platforms with computational screening and integrated medicinal chemistry support. | Revenue is available through integrated GPCR and ion-channel discovery programs that combine screening with hit progression. |
| Charles River joined X-Chem around a DNA-encoded library exceeding 15 billion compounds in October 2025. | Sponsors want several hit-finding routes under one accountable project lead that can coordinate assay and chemistry decisions. | Integrated CROs add external libraries to internal assays and medicinal chemistry across broader outsourced discovery programs. | Bundled hit identification and lead progression support larger outsourced programs with fewer scientific handoffs between organizations. |
Evotec, WuXi AppTec, Astex Pharmaceuticals, Sprint Bioscience and Cresset compete through screening depth, proprietary programs and computational design across separate commercial routes.
Source: Future Market Insights, Fragment-Based Drug Discovery and Drug Discovery Services Market Reports, 2026-2036.
Sygnature Discovery and Domainex cover protein preparation through medicinal chemistry as Charles River adds hit identification and WuXi AppTec documents ISO/IEC 27001 controls.
Who leads the fragment-based drug discovery market?
No single provider leads every fragment-based workflow across verified capability categories reviewed for this market. Evotec and WuXi AppTec cover screening through lead progression as Charles River combines services with several hit-identification routes.
Which suppliers document quality or information-security controls?
WuXi AppTec reports ISO/IEC 27001 certification across its main operating sites for managed information-security controls. During 2025, the company completed 741 quality audits and inspections plus 60 information-security audits with no critical findings.
Which companies provide physical and computational fragment-screening services?
Domainex and Sygnature Discovery combine physical fragment screening with protein science, structural biology and medicinal chemistry. Cresset concentrates on virtual screening and molecular design that help experimental teams prioritize compounds ahead of synthesis.
Which suppliers serve Europe and North America?
Charles River and WuXi AppTec operate discovery networks across Europe and North America for global programs. Sygnature Discovery operates in the United Kingdom and Canada as Domainex maintains Cambridge offices in the United Kingdom and Massachusetts.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Charles River Laboratories International, Inc. | Global | Fragment screening, assay development, structural biology and medicinal chemistry with several hit-identification routes. |
| Evotec SE | Global | Fragment screening, covalent fragments, structural biology and integrated medicinal chemistry. |
| WuXi AppTec Co., Ltd. | Asia, Europe and North America | cFBDD, DNA-encoded libraries, high-throughput screening and hit-to-lead execution. |
| Domainex Ltd. | United Kingdom and North America | Fragment screening, membrane-protein preparation, biophysics, X-ray crystallography and medicinal chemistry. |
| Sygnature Discovery Ltd. | United Kingdom and Canada | Fragment libraries, NMR, SPR, crystallography, computational design and medicinal chemistry. |
| Astex Pharmaceuticals | United Kingdom and partner markets | Fragment-based oncology programs and structure-guided lead progression for partnered assets. |
| Sprint Bioscience AB | Sweden and partner markets | Proprietary FBDD oncology assets developed for licensing or partnership. |
| Cresset | United Kingdom and international | Virtual screening, Flare molecular design, FEP and contract research support. |
Research Methodology
The companies illustrate market structure and do not represent a ranking based on revenue or corporate scale. Current official evidence supports roles from fragment screening through structural confirmation and fragment-to-lead chemistry or related computational design. Company websites and filings document capabilities as press releases and quality records document dated actions or site-specific controls. The 39.0% fragment screening platform share remains an FMI
